[1]
Atwood, B.K. et al. 2012. CB2: Therapeutic target-in-waiting. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 38, 1 (Jul. 2012), 16–20. DOI:https://doi.org/10.1016/j.pnpbp.2011.12.001.
[2]
Balon, R. 2006. Mood, anxiety, and physical illness: body and mind, or mind and body? Depression and Anxiety. 23, 6 (2006), 377–387. DOI:https://doi.org/10.1002/da.20217.
[3]
Brisbare-Roch, C. 2007. Promotion of sleep by targeting the orexin system in rats, dogs and humans. 13, 2 (2007), 150–155.
[4]
Carlos H. Schenck, M.W.M. 2005. Insights from studying human sleep disorders. 437, 7063 (2005), 1279–1285.
[5]
Carvalho, A.F. and Van Bockstaele, E.J. 2012. Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 38, 1 (Jul. 2012), 59–67. DOI:https://doi.org/10.1016/j.pnpbp.2012.01.008.
[6]
Cera, N. et al. 2014. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE. 9, 9 (Sep. 2014). DOI:https://doi.org/10.1371/journal.pone.0107145.
[7]
Cryan, J.F. and Kaupmann, K. 2005. Don’t worry ‘B’ happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences. 26, 1 (Jan. 2005), 36–43. DOI:https://doi.org/10.1016/j.tips.2004.11.004.
[8]
Eric J. Olson, K.R. 2013. Management of common sleep disorders. 88, 4 (2013), 231–238.
[9]
Freund, T.F. 2003. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends in Neurosciences. 26, 9 (Sep. 2003), 489–495. DOI:https://doi.org/10.1016/S0166-2236(03)00227-3.
[10]
H. Attarian, O.A. Treatment of disorders of hypersomnolence. 16, 9, 302–302.
[11]
Hill, A.J. et al. 2012. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics. 133, 1 (Jan. 2012), 79–97. DOI:https://doi.org/10.1016/j.pharmthera.2011.09.002.
[12]
Holmes, A. et al. 2003. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences. 24, 11 (Nov. 2003), 580–588. DOI:https://doi.org/10.1016/j.tips.2003.09.011.
[13]
Hoyer, D. and Jacobson, L.H. 2013. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides. 47, 6 (Dec. 2013), 477–488. DOI:https://doi.org/10.1016/j.npep.2013.10.009.
[14]
Kalueff, A.V. and Nutt, D.J. 2007. Role of GABA in anxiety and depression. Depression and Anxiety. 24, 7 (2007), 495–517. DOI:https://doi.org/10.1002/da.20262.
[15]
Kilduff, T.S. and Peyron, C. 2000. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences. 23, 8 (Aug. 2000), 359–365. DOI:https://doi.org/10.1016/S0166-2236(00)01594-0.
[16]
Levine, J. et al. 2001. Anxiety disorders and major depression, together or apart. Depression and Anxiety. 14, 2 (2001), 94–104. DOI:https://doi.org/10.1002/da.1051.
[17]
Luscher, B. et al. 2011. The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry. 16, 4 (Apr. 2011), 383–406. DOI:https://doi.org/10.1038/mp.2010.120.
[18]
Mahowald, M.W. and Schenck, C.H. 1992. Dissociated states of wakefulness and sleep. Neurology. 42 Suppl. 6, (1992), 44–52.
[19]
Mark W. Mahowald MD 2007. Pathophysiologic mechanisms in REM sleep behavior disorder. Current Neurology and Neuroscience Reports. 7, Issue 2 (Mar. 2007), 167–172. DOI:https://doi.org/10.1007/s11910-007-0013-7.
[20]
N.P. Robertson, K.J.P. 2014. Narcolepsy: environment, genes and treatment. 261, 8 (2014), 1644–1646.
[21]
Saper, C.B. and Scammell, T.E. 2013. Emerging therapeutics in sleep. Annals of Neurology. 74, 3 (Aug. 2013), 435–440. DOI:https://doi.org/10.1002/ana.24000.
[22]
Smith, K.S. and Rudolph, U. 2012. Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. Neuropharmacology. 62, 1 (Jan. 2012), 54–62. DOI:https://doi.org/10.1016/j.neuropharm.2011.07.026.
[23]
Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy: https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf.
[24]
Stores, G. 2003. Medication for sleep-wake disorders. Archives of Disease in Childhood. 88, 10 (Oct. 2003), 899–903. DOI:https://doi.org/10.1136/adc.88.10.899.
[25]
Strange, P.G. 1992. Brain biochemistry and brain disorders. Oxford University Press.